Our results indicated that along with the restraint of p-Src and p-AKT, the phosphorylation of c-Jun was inhibited, particularly under the joint effects of src inhibition and gemcitabine, which is in line with their inhibitory effects on deterring carcinogenesis and cancer progression. The gene discussed is SRC; the disease is cancer.